Minimizing Formulary-Driven Switching
Dr. Brent Moody discusses non-medical switching and formulary exclusions, how they affect both dermatology patients and practices, and what the dermatologist can do to advocate for their patients.
Pathogenesis of Dyspigmentation
From the 2021 Maui Derm Connect Meeting, Dr. Pearl Grimes reviews the pathogenesis of dyspigmentation, including hyperpigmentation and vitiligo.
State Rheumatology Orgs Against Non-Medical Switching
Dr. Madelaine Feldman discusses non-medical switching in the dermatology and rheumatology specialties, including the role of pharmacy benefit managers, and the Safe Step Act.
Monoclonal Antibodies for AD Treatment
Dr. James Treat discusses current and future monoclonal antibodies for atopic dermatitis treatment, including dupilumab, tralokinumab, and lebrikizumab.
Tips and Tricks to Minimize Local Injection Pain
From the 2021 Maui Derm Connect Meeting, Dr. Ilona Frieden offers several tips and tricks to minimize pain local injection pain for the pediatric patient.
BPDCN Podcast Series: The BPDCN Prognosis and Patient Referral
Listen to Part Three Here: In the final episode of our podcast series on BPDCN, dermatologist and dermatopathologist Dr. Whitney High discusses disease prognosis and offers guidance for referring patients to a hematologist oncologist. This is part 3 in The Dermatology Digest’s 3-part educational podcast series, sponsored by Stemline, which provides an overview of BPDCN, […]
Ted Rants #3 Listen Up! Hear Here!
PODCAST Ted Rants #3 Listen Up! Hear Here! Ted Talks but sometimes Ted Rants. This time? He sounds off on the (nearly) lost skill of taking a good patient history at the outset of the diagnostic process.
Cannabinoids Part 3: Proceed With Caution
In our cannabinoid series that examines current dermatologic pros and cons, Dr. Shawn Kwatra is cautiously optimistic, but advises to proceed with caution.
Cannabinoids Part 2: The Legal Framework
In our cannabinoid series that examines current dermatologic pros and cons, Dr. Adam Friedman talks CBD vs medical cannabis, dispensaries, and navigating state regulations.
Cannabinoids Part 1: The Future in Dermatology
In our cannabinoid series that examines current dermatologic pros and cons, Dr. Adam Friedman discusses the potential for CBD in dermatology, the science, and current clinical trial programs.